In the JAVELIN PARP Medley trial (Table 1), which evaluated the combination of avelumab and talazoparib in several cancer types including breast, ovarian, prostate, urothelial carcinoma, or NSCLC, alterations in DDR genes were not associated with response for patients with urothelial carcinoma or NSCLC, reinforcing the observation that DDR genes alterations play a key role in the biology of some cancers but are more neutral in others [291]. The gene discussed is PARP1; the disease is urothelial carcinoma.